Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFQB | ISIN: US9840156023 | Ticker-Symbol: 3XB0
NASDAQ
25.06.25 | 21:56
3,650 US-Dollar
+20,86 % +0,630
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XENETIC BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
XENETIC BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur XENETIC BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Xenetic Biosciences reports Q1 results2
14.05.Xenetic Biosciences, Inc. - 8-K, Current Report3
14.05.Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update237Strategic focus on exploratory investigator-initiated clinical studies with institutional partnersContinued progress of DNase I development program towards IND and first-in-human study for treatment...
► Artikel lesen
13.05.Xenetic Biosciences, Inc. - 10-Q, Quarterly Report1
XENETIC BIOSCIENCES Aktie jetzt für 0€ handeln
13.05.Xenetic Biosciences, Inc. - 10-K/A, Annual Report1
10.04.Xenetic Biosciences, Inc. - 8-K, Current Report1
09.04.Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment189- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer...
► Artikel lesen
26.03.Xenetic partners with PeriNess for cancer study in Israel3
26.03.Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma214Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc....
► Artikel lesen
19.03.Xenetic Biosciences reports FY results2
19.03.Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results220Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus on exploratory investigator-initiated clinical studies...
► Artikel lesen
19.03.Xenetic Biosciences, Inc. - 8-K, Current Report2
18.03.Xenetic Biosciences, Inc. - 10-K, Annual Report1
13.03.Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses235Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not...
► Artikel lesen
27.02.Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer Spring Scientific 2025 Cell Therapy Meeting259FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...
► Artikel lesen
17.12.24Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment262Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement...
► Artikel lesen
16.12.24Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform296Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc....
► Artikel lesen
05.12.24Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program414Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA /...
► Artikel lesen
22.11.24Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment294Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC)...
► Artikel lesen
21.11.24Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis257Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1